Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provid… Read more
Aurisco Pharmaceutical Co Ltd (605116) - Net Assets
Latest net assets as of June 2025: CN¥2.43 Billion CNY
Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) has net assets worth CN¥2.43 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.90 Billion) and total liabilities (CN¥1.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.43 Billion |
| % of Total Assets | 62.25% |
| Annual Growth Rate | 18.75% |
| 5-Year Change | 68.31% |
| 10-Year Change | N/A |
| Growth Volatility | 9.54 |
Aurisco Pharmaceutical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Aurisco Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aurisco Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual net assets of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.33 Billion | +18.50% |
| 2023-12-31 | CN¥1.97 Billion | +16.83% |
| 2022-12-31 | CN¥1.68 Billion | +11.68% |
| 2021-12-31 | CN¥1.51 Billion | +8.86% |
| 2020-12-31 | CN¥1.39 Billion | +41.74% |
| 2019-12-31 | CN¥977.28 Million | +24.09% |
| 2018-12-31 | CN¥787.54 Million | +15.15% |
| 2017-12-31 | CN¥683.95 Million | +15.96% |
| 2016-12-31 | CN¥589.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aurisco Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 210.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.12 Billion | 48.16% |
| Other Components | CN¥1.21 Billion | 51.84% |
| Total Equity | CN¥2.33 Billion | 100.00% |
Aurisco Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Aurisco Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Volex plc
PINK:VLXGF
|
$305.63 Million |
|
K-Bro Linen Inc.
TO:KBL
|
$305.68 Million |
|
Jiangsu WELLE Environmental Co Ltd
SHE:300190
|
$305.70 Million |
|
Liuzhou Chemical Industry Co Ltd
SHG:600423
|
$305.74 Million |
|
Flytech Technology Co Ltd
TW:6206
|
$305.48 Million |
|
Shenzhen Sosen Electronics Co.Ltd.
SHE:301002
|
$305.47 Million |
|
Propel Funeral Partners Limited
PINK:PFPLF
|
$305.43 Million |
|
Regal Partners Ltd
AU:RPL
|
$305.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aurisco Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,967,585,190 to 2,331,528,722, a change of 363,943,532 (18.5%).
- Net income of 354,792,033 contributed positively to equity growth.
- Dividend payments of 94,816,215 reduced retained earnings.
- Other factors increased equity by 103,967,713.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥354.79 Million | +15.22% |
| Dividends Paid | CN¥94.82 Million | -4.07% |
| Other Changes | CN¥103.97 Million | +4.46% |
| Total Change | CN¥- | 18.50% |
Book Value vs Market Value Analysis
This analysis compares Aurisco Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.35x to 4.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.48 | CN¥25.70 | x |
| 2017-12-31 | CN¥1.84 | CN¥25.70 | x |
| 2018-12-31 | CN¥2.19 | CN¥25.70 | x |
| 2019-12-31 | CN¥2.73 | CN¥25.70 | x |
| 2020-12-31 | CN¥3.70 | CN¥25.70 | x |
| 2021-12-31 | CN¥3.75 | CN¥25.70 | x |
| 2022-12-31 | CN¥4.13 | CN¥25.70 | x |
| 2023-12-31 | CN¥4.84 | CN¥25.70 | x |
| 2024-12-31 | CN¥5.74 | CN¥25.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aurisco Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.04%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.66x
- Recent ROE (15.22%) is above the historical average (13.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 15.70% | 14.69% | 0.76x | 1.42x | CN¥31.50 Million |
| 2017 | 6.54% | 8.21% | 0.67x | 1.19x | CN¥-23.67 Million |
| 2018 | 17.37% | 23.78% | 0.62x | 1.17x | CN¥58.08 Million |
| 2019 | 19.05% | 32.00% | 0.53x | 1.13x | CN¥88.40 Million |
| 2020 | 11.35% | 21.79% | 0.47x | 1.11x | CN¥18.70 Million |
| 2021 | 11.20% | 21.00% | 0.47x | 1.14x | CN¥18.09 Million |
| 2022 | 12.58% | 20.92% | 0.50x | 1.21x | CN¥43.28 Million |
| 2023 | 14.71% | 22.92% | 0.49x | 1.31x | CN¥92.66 Million |
| 2024 | 15.22% | 24.04% | 0.38x | 1.66x | CN¥121.64 Million |
Industry Comparison
This section compares Aurisco Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aurisco Pharmaceutical Co Ltd (605116) | CN¥2.43 Billion | 15.70% | 0.61x | $305.60 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |